Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 1:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 117 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Erythema Clear all
Withdrawn Not applicable Interventional

Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study

NCT02795143
View directory record Official record
Conditions
Toxic Epidermal Necrolysis
Interventions
Isotretinoin, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 69 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Jul 21, 2026, 1:25 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

B-19 Parvovirus Vaccine Study

NCT00379938
View directory record Official record
Conditions
Parvovirus B19 Infection
Interventions
VAI-VP705 (parvovirus B-19 vaccine), Placebo, MF-59
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
3
States / cities
Baltimore, Maryland • Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2011 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Phase 2 Interventional

Prolongation of Contact Lens Comfortable Wear Duration by CLM2 Topical Gel

NCT03994406
View directory record Official record
Conditions
Contact Lens Discomfort, Contact Lens-induced Corneal Disorder, Contact Lens Acute Red Eye, Contact Lens-induced Corneal Fluorescein Staining
Interventions
CLM2 topical gel, Placebo topical gel
Drug
Lead sponsor
Glia, LLC
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Jul 21, 2026, 1:25 PM EDT
Completed No phase listed Observational Results available

Safety and Feasibility of Prima-Temp Thermometer Patch

NCT01587014
View directory record Official record
Conditions
Erythema, Edema, Papules White, Eruption
Interventions
Not listed
Lead sponsor
Poudre Valley Health System
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Loveland, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 19, 2017 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effective Treatments for Jellyfish Stings

NCT02015195
View directory record Official record
Conditions
Jellyfish Stings
Interventions
Acetic Acid (5%), Sodium Bicarbonate Slurry (50%), Papain Slurry (70%), Ammonia (10%), Lidocaine (4%), Isopropyl Alcohol (70%), Hot Tap Water (40 degrees Celsius), No treatment
Other · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2015 · Synced Jul 21, 2026, 1:25 PM EDT
Recruiting Phase 2 Interventional

Efficacy and Safety Study of Dovramilast in People With Leprosy Type 2 Reaction

NCT07172659
View directory record Official record
Conditions
Erythema Nodosum Leprosum
Interventions
Dovramilast, Prednisolone, Thalidomide
Drug
Lead sponsor
Medicines Development for Global Health
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Effects of PRK 124 Lotion in Acne Rosacea

NCT00580723
View directory record Official record
Conditions
Acne Rosacea
Interventions
PRK 124
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
21 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Not applicable Interventional Results available

Study of the 532 nm KTP Laser for the Treatment of Poikiloderma of Civatte

NCT01491620
View directory record Official record
Conditions
Poikiloderma of Civatte, Dyschromia, Pigmentation Disorders, Telangiectasia, Photosensitivity Disorders
Interventions
532 nm KTP laser
Device
Lead sponsor
Cutera Inc.
Industry
Eligibility
35 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Edina, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Phase 4 Interventional Results available

Mirvaso in Use Study

NCT02249065
View directory record Official record
Conditions
Rosacea
Interventions
Brimonidine
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
Fort Smith, Arkansas • Newport Beach, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2022 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Phase 1 Interventional

A Study Comparing Oxymetazoline 1% Cream to RHOFADE

NCT05148689
View directory record Official record
Conditions
Bioequivalence
Interventions
Oxymetazoline hydrochloride Cream, 1%, Rhofade™ (oxymetazoline) cream, 1%, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Phase 3 Interventional Results available

Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

NCT01318733
View directory record Official record
Conditions
Rosacea
Interventions
CD07805/47 gel 0.5%
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
27
States / cities
Santa Monica, California • Denver, Colorado • Longmont, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Phase 1 Interventional Results available

Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea

NCT01579084
View directory record Official record
Conditions
Rosacea, Erythema
Interventions
AGN-199201 Formulation A, AGN-199201 Formulation B, AGN-199201 Formulation C, AGN-199201 Vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Phase 2 Interventional

A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.

NCT00249782
View directory record Official record
Conditions
Rosacea
Interventions
Vehicle control, 2x/day, ACZONE (dapsone) Gel, 5%, 2x/day, ACZONE (dapsone) Gel, 5%, 1x/day, MetroGel® (metronidazole gel), 1.0% 1x/day, ACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM)
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
26
States / cities
Birmingham, Alabama • Tucson, Arizona • Fremont, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 29, 2011 · Synced Jul 21, 2026, 1:25 PM EDT
Not yet recruiting Phase 1 Interventional

Subconjunctival Humira for Boston Keratoprosthesis

NCT06926478
View directory record Official record
Conditions
Penetrating Keratoplasty, Multiple Graft Failure, Ocular Cicatricial Pemphigoid, Stevens-Johnson Syndrome
Interventions
Adalimumab Injection
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Phase 3 Interventional

A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness

NCT06803654
View directory record Official record
Conditions
Ocular Redness
Interventions
BTOS-HA, Lumify®
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
11
States / cities
Glendale, California • Newport Beach, California • Northbrook, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Human Repeat Insult Patch Test to Evaluate Personal Lubricants

NCT02737631
View directory record Official record
Conditions
Erythema, Edema
Interventions
"Chameleon" Personal Lubricant
Device
Lead sponsor
Church & Dwight Company, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
222 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Union, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Not applicable Interventional Results available

Clinical Trial of the invisaRED® IR REHAB Device When Used as an Adjunctive Therapy for Nociceptive Musculoskeletal Pain

NCT06393088
View directory record Official record
Conditions
Nociceptive Pain, Musculoskeletal Pain
Interventions
IR REHAB, Sham
Device
Lead sponsor
IR Technology, LLC
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Woodstock, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Open-label, Non Significant Risk, Adhesive Wear Validation Study for the On Body Drug Delivery Device Component of the SQIN-01 Furosemide Infusor (Infusor Device)

NCT04836572
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
3M 1529 Adhesive Tape
Other
Lead sponsor
SQ Innovation, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Marlborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

50 Human Subject Repeat Insult Patch Test

NCT04498676
View directory record Official record
Conditions
Erythema, Sensitisation
Interventions
CB-0002B
Other
Lead sponsor
CAGE Bio Inc.
Industry
Eligibility
21 Years to 67 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New City, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Jul 21, 2026, 1:25 PM EDT
Completed No phase listed Observational Results available

Study of Inter- and Intra-rater Reliability of the Clinician Erythema Assessment Scale

NCT01636765
View directory record Official record
Conditions
Erythema, Rosacea
Interventions
No Intervention
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance

NCT04831047
View directory record Official record
Conditions
Ptosis, Eyelid, Conjunctiva Inflamed, Eye Manifestations
Interventions
Oxymetazoline hydrochloride 0.1% ophthalmic solution, Placebo
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 23, 2023 · Synced Jul 21, 2026, 1:25 PM EDT
Completed No phase listed Observational

Urinary Continence Index for Prediction of Urinary Incontinence in Older Women

NCT01479816
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Not listed
Lead sponsor
Ananias Diokno
Other
Eligibility
55 Years and older · Female only
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Rochester, Michigan • Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Jul 21, 2026, 1:25 PM EDT
Completed Not applicable Interventional

A Pilot Study of Warm and Cold Compress to Reduce Injection Site Erythema Due to Peginterferon-beta-1a in MS

NCT02490943
View directory record Official record
Conditions
MS (Multiple Sclerosis), Erythema
Interventions
Warm Compress Before Injection, Cold Compress After Injection
Other
Lead sponsor
Brown, Theodore R., M.D., MPH
Individual
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Jul 21, 2026, 1:25 PM EDT
Withdrawn Phase 2 Interventional

Celecoxib in Preventing Skin Cancer

NCT00025051
View directory record Official record
Conditions
Non-melanomatous Skin Cancer
Interventions
celecoxib, anti-cytokine therapy, antiangiogenesis therapy, biological therapy, cancer prevention intervention, chemoprevention of cancer, growth factor antagonist therapy
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
20 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Jul 21, 2026, 1:25 PM EDT